SCHEMBL4017657

SCHEMBL4017657

O=C(NC1CCN(c2ncnc3cc(Cl)ccc23)CC1)c1ccc(F)cc1.O=C(NC1CCN(c2ncnc3cc(Cl)ccc23)CC1)c1ccccc1I

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PAK1 Q13153 8/20 0.54
CNR1 P21554 5/20 0.51
CNR2 P34972 4/20 0.51
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
SUV39H1 O43463 1/20 0.47
PRMT1 Q99873 1/20 0.47
SMYD3 Q9H7B4 1/20 0.47
SIGMAR1 Q99720 2/20 0.43
SLC6A12 P48065 1/20 0.43
TMEM97 Q5BJF2 1/20 0.43
MCHR1 Q99705 1/20 0.43
CCNE1 P24864 1/20 0.43
CDK2 P24941 1/20 0.43
AKT1 P31749 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4024034 0.92 PAK1 (0.55) PAK1CNR1CNR2CYP1A2CYP2D6
SCHEMBL4017884 0.91 PAK1 (0.63) PAK1CNR1CNR2CYP1A2CYP2D6
SCHEMBL4018947 0.88 MAPK1 (0.49) CCNE1CDK2
SCHEMBL4023244 0.85 CNR1 (0.57) PAK1CNR1CNR2CYP1A2CYP2D6
SCHEMBL4018106 0.84 CNR1 (0.58) PAK1CNR1CNR2CYP1A2CYP2D6
SCHEMBL4022779 0.83 CYP1A2 (0.54) PAK1CNR1CNR2CYP1A2CYP2D6
SCHEMBL4023238 0.83 CNR1 (0.51) PAK1CNR1CNR2CYP1A2CYP2D6
SCHEMBL4024856 0.83 PAK1 (0.67) PAK1CNR1CNR2CYP1A2CYP2D6
SCHEMBL4023489 0.83 CYP1A2 (0.56) PAK1CNR1CNR2CYP1A2CYP2D6
SCHEMBL4016285 0.83 CNR1 (0.58) PAK1CNR1CNR2CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066654-A1 N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS Bayer Schering Pharma AG (DE) 2009-06-10 EP claimed
WO-2008028691-A1 N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-13 WO claimed